These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 22261982)

  • 1. The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the dose-response curves of SSRIs.
    Preskorn SH
    J Psychiatr Pract; 2012 Jan; 18(1):38-45. PubMed ID: 22261982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serotonin transporter occupancy of high-dose selective serotonin reuptake inhibitors during major depressive disorder measured with [11C]DASB positron emission tomography.
    Voineskos AN; Wilson AA; Boovariwala A; Sagrati S; Houle S; Rusjan P; Sokolov S; Spencer EP; Ginovart N; Meyer JH
    Psychopharmacology (Berl); 2007 Sep; 193(4):539-45. PubMed ID: 17497139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.
    Meyer JH; Wilson AA; Sagrati S; Hussey D; Carella A; Potter WZ; Ginovart N; Spencer EP; Cheok A; Houle S
    Am J Psychiatry; 2004 May; 161(5):826-35. PubMed ID: 15121647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biaryls as potent, tunable dual neurokinin 1 receptor antagonists and serotonin transporter inhibitors.
    Degnan AP; Tora GO; Han Y; Rajamani R; Bertekap R; Krause R; Davis CD; Hu J; Morgan D; Taylor SJ; Krause K; Li YW; Mattson G; Cunningham MA; Taber MT; Lodge NJ; Bronson JJ; Gillman KW; Macor JE
    Bioorg Med Chem Lett; 2015 Aug; 25(15):3039-43. PubMed ID: 26048800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtherapeutic doses of SSRI antidepressants demonstrate considerable serotonin transporter occupancy: implications for tapering SSRIs.
    Shapiro BB
    Psychopharmacology (Berl); 2018 Sep; 235(9):2779-2781. PubMed ID: 30097698
    [No Abstract]   [Full Text] [Related]  

  • 6. Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder.
    Lundberg J; Tiger M; Landén M; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2012 Sep; 15(8):1167-72. PubMed ID: 22243688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.
    Lelas S; Li YW; Wallace-Boone TL; Taber MT; Newton AE; Pieschl RL; Davis CD; Molski TF; Newberry KS; Parker MF; Gillman KW; Bronson JJ; Macor JE; Lodge NJ
    Neuropharmacology; 2013 Oct; 73():232-40. PubMed ID: 23770339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serotonin transporter occupancy by escitalopram and citalopram in the non-human primate brain: a [(11)C]MADAM PET study.
    Finnema SJ; Halldin C; Bang-Andersen B; Bundgaard C; Farde L
    Psychopharmacology (Berl); 2015 Nov; 232(21-22):4159-67. PubMed ID: 25980484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Ketamine Binding of the Serotonin Transporter in Humans with Positron Emission Tomography.
    Spies M; James GM; Berroterán-Infante N; Ibeschitz H; Kranz GS; Unterholzner J; Godbersen M; Gryglewski G; Hienert M; Jungwirth J; Pichler V; Reiter B; Silberbauer L; Winkler D; Mitterhauser M; Stimpfl T; Hacker M; Kasper S; Lanzenberger R
    Int J Neuropsychopharmacol; 2018 Feb; 21(2):145-153. PubMed ID: 29045739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram.
    Lundberg J; Christophersen JS; Petersen KB; Loft H; Halldin C; Farde L
    Int J Neuropsychopharmacol; 2007 Dec; 10(6):777-85. PubMed ID: 17201996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram.
    Klein N; Sacher J; Geiss-Granadia T; Attarbaschi T; Mossaheb N; Lanzenberger R; Pötzi C; Holik A; Spindelegger C; Asenbaum S; Dudczak R; Tauscher J; Kasper S
    Psychopharmacology (Berl); 2006 Oct; 188(3):263-72. PubMed ID: 16955282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapering of SSRI treatment to mitigate withdrawal symptoms.
    Horowitz MA; Taylor D
    Lancet Psychiatry; 2019 Jun; 6(6):538-546. PubMed ID: 30850328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [
    Kim E; Howes OD; Kim BH; Chon MW; Seo S; Turkheimer FE; Lee JS; Lee YS; Kwon JS
    Clin Pharmacokinet; 2017 Apr; 56(4):371-381. PubMed ID: 27557550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-course of serotonin transporter occupancy by single dose of three SSRIs in human brain: A positron emission tomography study with [(11)C]DASB.
    Arakawa R; Tateno A; Kim W; Sakayori T; Ogawa K; Okubo Y
    Psychiatry Res Neuroimaging; 2016 May; 251():1-6. PubMed ID: 27082864
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined α7 nicotinic acetylcholine receptor agonism and partial serotonin transporter inhibition produce antidepressant-like effects in the mouse forced swim and tail suspension tests: a comparison of SSR180711 and PNU-282987.
    Andreasen JT; Redrobe JP; Nielsen EØ
    Pharmacol Biochem Behav; 2012 Jan; 100(3):624-9. PubMed ID: 22108649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design for an investigation to optimize selective serotonin reuptake inhibitor treatment for pregnant women with depression.
    Avram MJ; Stika CS; Rasmussen-Torvik LJ; Ciolino JD; Pinheiro E; George AL; Wisner KL
    Clin Pharmacol Ther; 2016 Jul; 100(1):31-3. PubMed ID: 27037844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [[Pathophysiology and treatment of depression: a review of PET imaging of serotonin transporter].
    Matsumoto R; Suhara T
    Nihon Yakurigaku Zasshi; 2007 Dec; 130(6):464-8. PubMed ID: 18079596
    [No Abstract]   [Full Text] [Related]  

  • 18. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.
    Suhara T; Takano A; Sudo Y; Ichimiya T; Inoue M; Yasuno F; Ikoma Y; Okubo Y
    Arch Gen Psychiatry; 2003 Apr; 60(4):386-91. PubMed ID: 12695316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-dependent effects of the selective serotonin reuptake inhibitor citalopram: A combined SPECT and phMRI study.
    Schrantee A; Solleveld MM; Schwantje H; Bruin WB; Mutsaerts HM; Adriaanse SM; Lucassen P; Booij J; Reneman L
    J Psychopharmacol; 2019 Jun; 33(6):660-669. PubMed ID: 30887865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose-finding study of duloxetine based on serotonin transporter occupancy.
    Takano A; Suzuki K; Kosaka J; Ota M; Nozaki S; Ikoma Y; Tanada S; Suhara T
    Psychopharmacology (Berl); 2006 Apr; 185(3):395-9. PubMed ID: 16506079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.